Quantcast

Latest Bite Stories

2010-07-01 12:00:00

SAN FRANCISCO, July 1 /PRNewswire-USNewswire/ -- As Californians head outdoors to enjoy the summer sun they can be exposed to potential dangers as well. The California Poison Control System (CPCS) offers tips for staying safe and happy this season. CPCS (www.calpoison.org) is available at 1-800-222-1222, 24 hours a day, seven days a week for immediate expert help and information in case of exposure to summer hazards. "With school out and the sun shining Californians are heading...

2010-06-29 07:30:00

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating the potency of new product candidates based on the Company's proprietary BiTE® antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells. Results published in PNAS characterize new BiTE antibodies...

2010-06-15 15:45:30

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma. The compound also showed partial or complete tumor regression and improved survival in a dose-dependent manner in preclinical efficacy models in rodents, without associated toxicity. BRAF mutations are found in about 8...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing. Blinatumomab is the first in a...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable,...

2010-06-08 07:00:00

BETHESDA, Md., June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that Christian Itin, Ph.D., Micromet's President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences: Jefferies 2010 Global Life Sciences Conference Wednesday, June 9, at 2 PM ET Grand Hyatt, New...

2010-06-07 08:00:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors. MT110 is designed to direct a patient's T cells, the immune system's most potent killer cells, against cancer cells that...

2010-05-21 06:45:00

BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences. Blinatumomab (MT103), the Company's lead product candidate, will be the subject of two oral presentations at the 15th Annual Congress of the...

2010-05-05 06:30:00

BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010. "With the proceeds from our recent financing, we are well-positioned to conduct the planned European pivotal study of blinatumomab in patients with acute lymphoblastic leukemia and other studies...

2010-05-05 06:00:00

INGELHEIM, Germany and BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Boehringer Ingelheim and Micromet, Inc. (Nasdaq: MITI) announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma. Despite recent advances in the treatment of multiple myeloma, the disease remains largely incurable. While the majority of patients initially respond to treatment, almost all of...


Latest Bite Reference Libraries

0_e288c9a7e7e932afbeba3516c20e64f2
2009-06-16 22:38:30

The Brown Recluse Spider (Loxosceles reclusa) is a species of arachnid that is native to the USA from the southern Midwest south to the Gulf of Mexico. It can be found in Canada as well around southeast Ontario, and southern Quebec. Its range lies from southeastern Nebraska through southern Iowa, Illinois, and Indiana to southwestern Ohio. In the south, it is native from central Texas to western Georgia. It is not usually found west of the Rocky Mountains. Contrary to popular belief, this...

More Articles (1 articles) »
Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related